PT - JOURNAL ARTICLE AU - Alex Chenchik AU - Michael Makhanov AU - Russell Darst AU - Tianbing Liu AU - Lester Kobzik TI - 69 Immunophenotyping of TCR and BCR clonotypes AID - 10.1136/jitc-2021-SITC2021.069 DP - 2021 Nov 01 TA - Journal for ImmunoTherapy of Cancer PG - A77--A77 VI - 9 IP - Suppl 2 4099 - http://jitc.bmj.com/content/9/Suppl_2/A77.short 4100 - http://jitc.bmj.com/content/9/Suppl_2/A77.full SO - J Immunother Cancer2021 Nov 01; 9 AB - Background T-cell receptor (TCR) and B-cell receptor (BCR) repertoire profiling holds great potential for understanding disease mechanisms and for the development of new therapeutics in infectious diseases, autoimmunity and in immuno-oncology. However, this potential could be greatly improved by combining information about receptor clonotypes with immuno-phenotypes of T and B cells.Methods To facilitate these studies, we developed a novel technology for combined profiling of all human TCR and BCR variable regions and phenotypic characterization of immune cells in bulk and at the single-cell level in PBMC and immune cell fraction samples. The developed TCR/BCR Immunophenotyping method involves multiplex RT-PCR amplification and sequencing of CDR3 regions of TCR and BCR genes and a set of the most informative T- and B-cell phenotyping genes. Bioinformatics analysis of NGS data allows profiling of TCR/BCR clonotypes, and identification of major immune cell subtypes and their activation status.Results Data will be presented showing how combined TCR/BCR clonotype analysis combined with targeted expression profiling of immune cells can be applied for large-scale discovery of novel cell typing and activation biomarkers in several immune-responsive model systems.Conclusions Preliminary studies demonstrate the assay has unparalleled throughput, sensitivity, and improved cost-effectiveness for high-throughput immunity biomarker discovery applications.